THE 30-SECOND OVERVIEW
NAD+ dosage research quick start
The NAD+ dosing literature has a split in it that most write-ups skip. Nearly every controlled human trial tested a precursor, nicotinamide riboside or nicotinamide mononucleotide, and not NAD+ itself. Reading precursor trial doses as NAD+ doses conflates two different compounds with different pharmacokinetics.
Check the formulation
NAD+ 250 mg vial. Other formats and blends may have different strengths.
Amount ≠ schedule
Concentration arithmetic does not determine dosing frequency or a safe human daily amount.
LABORATORY CONCENTRATION MATH
NAD+ dosage calculator
Calculate the amount in a laboratory sample of the 250 mg NAD+ vial. Enter the final solution volume, not the container capacity.
Enter positive volumes; the sample cannot exceed the final solution volume.
Illustrative arithmetic only. These inputs are not recommended preparation volumes or doses. This calculator does not recommend a route or schedule for human use.
Why the distinction matters
NAD+ is a coenzyme involved in redox reactions and in the activity of enzymes including sirtuins and PARPs. It is not stable and freely absorbed the way a small drug molecule is, and the intact molecule does not cross cell membranes readily.
That is why the research went the precursor route. NR and NMN are smaller, absorb more predictably, and cells convert them to NAD+ through the salvage pathway. When a trial reports raising NAD+ levels, it usually means it gave a precursor and measured NAD+ in blood or tissue afterwards.
So a dosing question about NAD+ has two answers depending on which compound you mean, and they are not interchangeable.
What the NR trials used
Nicotinamide riboside has the more developed human record. Martens and colleagues in Nature Communications, 2018, ran a placebo-controlled crossover in healthy middle-aged and older adults using 500mg twice daily for six weeks, so 1000mg per day. That trial reported increased blood NAD+ levels and was designed with safety and tolerability as primary considerations.
Other NR work has used lower quantities, and the range across published trials runs from around 100mg per day up to 1000mg per day. The consistent finding across them is dose-dependent elevation of NAD+ in blood. What is less consistent is whether that elevation produces the downstream outcomes researchers are interested in, which is a different question and less settled.
What the NMN trials used
Nicotinamide mononucleotide trials have generally used smaller quantities. Yoshino and colleagues in Science, 2021, used 250mg daily in postmenopausal women with prediabetes over ten weeks and reported changes in muscle insulin sensitivity. Several other NMN trials cluster in the same low hundreds of milligrams per day.
The NMN record is younger than the NR record and the trials are smaller, so the evidence base is thinner even where the reported effects look interesting.
What is known about direct NAD+
Very little, in dosing terms. Intravenous NAD+ has been used clinically and in small studies, but the published protocols are sparse and the quantities vary widely between them. There is no equivalent of the Martens or Yoshino trials for direct NAD+ administration.
Intranasal NAD+ has even less. Whether NAD+ delivered intranasally, as in an NAD+ nasal spray, reaches the compartments researchers care about, and in what proportion, has not been characterised in the way oral precursor absorption has.
This is not an argument against studying direct NAD+. It is a statement about which claims the literature currently supports, and dosing is not one of them.
Reconstitution and handling
NAD+ and its precursors are supplied lyophilised. Handling is straightforward, with two points worth attention.
NAD+ is sensitive to pH and to repeated freeze-thaw cycles, more so than a simple peptide. Prepare what a protocol needs rather than reconstituting a whole vial and storing the solution across many sessions.
Concentration comes from diluent volume, and this is where protocols drift. Reconstituting the same quantity in 1mL versus 2mL gives a twofold difference, so a volume carried over from a differently prepared vial is wrong by that factor. Recalculate for each vial rather than reusing a number. Our peptide calculator does the arithmetic.
What the research does not establish
The precursor trials measured NAD+ levels in blood. Blood is accessible, not necessarily representative, and tissue-level NAD+ is what the mechanistic hypotheses are about. Raising a blood marker and changing tissue biology are separate claims.
Trial durations were weeks, not years. Questions about long-term administration are open rather than answered either way.
And the precursors themselves are not equivalent. NR and NMN enter the salvage pathway at different points, and the assumption that a milligram of one equals a milligram of the other is an assumption, not a finding.
The takeaway
If the question is about precursors, the published human protocols are reasonably clear: NR trials up to 1000mg per day, NMN trials commonly around 250mg per day, over weeks. If the question is about NAD+ itself, there is no comparable protocol to cite, and any figure offered for it is not coming from a controlled trial. We stock NAD+ for sale and NMN for sale as separate research lines.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Martens, C. R., Denman, B. A., Mazzo, M. R., et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9(1), 1286.
2. Yoshino, M., Yoshino, J., Kayser, B. D., et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224-1229.
